Arrogene, Inc is a biotechnology firm, which develops nano-diagnostic and therapeutic agents that are based on natural polymer and beta-polymalic acid. Arrogene, Inc has officially announced that Dr. Jack will assume the title of Chairman and Executive Chairman effective immediately.
He Kavanaugh is a widely reputed business executive who has successfully led and guided a number of biotech and medical science organizations.
The Arrogene’s technology was developed at the Cedars-Sinai Medical Center, under the right guidance and leadership of Julia Ljubimova. He is the MD, Ph.D., director of the Nanomedicine Research Center associated with the Maxine Dunitz Neurosurgical Research Institute at Cedars-Sinai. Moreover, he is the founder of Arrogene also act and a lead scientist.
The other member who gave a notable contribution to the technology was from Eggehard Holler, PhD, research scientist in the Maxine Dunitz Neurosurgical Research Institute, also Keith Black who is MD, chair of the Cedars-Sinai Department of Neurosurgery, director of the Maxine Dunitz Neurosurgical Institute as well as the Ruth and Lawrence Harvey Chair in Neuroscience at Cedars-Sinai.
This technology is completely licensed by the Cedars-Sinai to Arrogene under a unique license agreement on 23 December 2009 and modified from time to time. Arrogene has created a proprietary technology for the therapeutics’ delivery by a number of bio-barriers that includes the blood-brain barrier, to cancer cells.
In addition to this, the same nano-drug can be able to activate the anti-tumor immune response of an individual patient. This technology is beneficial for numerous pathological conditions including cancer.
In this occasion, Dr. Kavanaugh stated, “I am truly thrilled to be joining Arrogene,” “Dr. Ljubimova has led an incredible team in developing strides that I believe will have a very unique and profound impact on both cancer therapy (with multiple targets) as well as diagnostic and in-therapy assessments.”
Dr. Jack is the founder ZetaRX also served as the Chairman and CEO of the company, the core of Juno Therapeutics that reported the best outcome ever in the history of terminal cancer therapy that has obtained a market cap of approximately $6 billion.
Dr. Ljubimova mentioned his thoughts, “As a company founder, I strongly believe that in Dr. Kavanaugh’s professional hands the company will be able to significantly contribute to the innovative treatment of cancer and other pathological conditions.”
Dr. Jack Kavanaugh has managed numerous organizations at every stage from beginning to profitable sale and has clearly focused on medical and physical sciences technology. He developed various strategies for the profitable and non-profitable organizations that have made a significant impact on the welfare of society.
Dr. Black mentioned, “I am delighted that Dr. Jack Kavanaugh is joining Arrogene as Executive Chairman. Dr. Kavanaugh brings a wealth of experience in moving novel discoveries from the bench to therapeutics for human disorders. His vision and leadership ability will greatly accelerate the commercial development of Arrogene’s nano-technology platforms.”